When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Aug 26

PMID 36015215

Authors

Linna Yu

Yi Jin

Mingjie Song

Yu Zhao

Huaqing Zhang

Affiliations

Soon will be listed here.

Abstract

Recent significant strides of natural compounds in immunomodulation have highlighted their great potential against cancer. Despite many attempts being made for cancer immunotherapy, the biomedical application of natural compounds encounters a bottleneck because of their unclear mechanisms, low solubility and bioavailability, and limited efficacy. Herein, we summarize the immune regulatory mechanisms of different natural compounds at each step of the cancer-immunity cycle and highlight their anti-tumor potential and current limitations. We then propose and present various drug delivery strategies based on nanotechnology, including traditional nanoparticles (NPs)-based delivery strategies (lipid-based NPs, micelles, and polysaccharide/peptide/protein-based NPs) and novel delivery strategies (cell-derived NPs and carrier-free NPs), thus providing solutions to break through existing bottlenecks. Furthermore, representative applications of nature-inspired nanomedicines are also emphasized in detail with the advantages and disadvantages discussed. Finally, the challenges and prospects of natural compounds for cancer immunotherapy are provided, hopefully, to facilitate their far-reaching development toward clinical translation.

Citing Articles

PVA-Stabilized and Coassembled Nano/Microparticles with High Payload of Dual Phytochemicals for Enhanced Antibacterial and Targeting Effect.

Yang H, Yang Y, Wang J, Dong Z, Wang J, Ma Y ACS Omega. 2024; 9(40):41990-42001.

PMID: 39398137 PMC: 11465548. DOI: 10.1021/acsomega.4c06925.

Antibody Drug Conjugates for Cancer Therapy: From Metallodrugs to Nature-Inspired Payloads.

Tonon G, Rizzolio F, Visentin F, Scattolin T Int J Mol Sci. 2024; 25(16).

PMID: 39201338 PMC: 11355040. DOI: 10.3390/ijms25168651.

Natural compounds-based nanomedicines for cancer treatment: Future directions and challenges.

Andreani T, Cheng R, Elbadri K, Ferro C, Menezes T, Dos Santos M Drug Deliv Transl Res. 2024; 14(10):2845-2916.

PMID: 39003425 PMC: 11385056. DOI: 10.1007/s13346-024-01649-z.

A review of natural products targeting tumor immune microenvironments for the treatment of lung cancer.

Yao P, Liang S, Liu Z, Xu C Front Immunol. 2024; 15:1343316.

PMID: 38361933 PMC: 10867126. DOI: 10.3389/fimmu.2024.1343316.

Emerging Trends in Nano-Driven Immunotherapy for Treatment of Cancer.

Kandasamy G, Karuppasamy Y, Krishnan U Vaccines (Basel). 2023; 11(2).

PMID: 36851335 PMC: 9968063. DOI: 10.3390/vaccines11020458.

References

Lu H, Yang Y, Gad E, Wenner C, Chang A, Larson E . Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res. 2010; 17(1):67-76. PMC: 3017241. DOI: 10.1158/1078-0432.CCR-10-1763. View

Fu Y, Lin Q, Zhang Z, Zhang L . Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity. Acta Pharm Sin B. 2020; 10(3):414-433. PMC: 7049610. DOI: 10.1016/j.apsb.2019.08.010. View

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

Bae M, Kim S, Jeong J, Lee Y, Kim H, Kim S . Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol Rep. 2006; 15(6):1557-62. View

Huang H, Fang J, Fan X, Miyata T, Hu X, Zhang L . Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses. Front Pharmacol. 2020; 11:1009. PMC: 7360845. DOI: 10.3389/fphar.2020.01009. View

Dai L, Li X, Yao M, Niu P, Yuan X, Li K . Programmable prodrug micelle with size-shrinkage and charge-reversal for chemotherapy-improved IDO immunotherapy. Biomaterials. 2020; 241:119901. DOI: 10.1016/j.biomaterials.2020.119901. View

Hardman C, Ho S, Shimizu A, Luu-Nguyen Q, Sloane J, Soliman M . Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy. Nat Commun. 2020; 11(1):1879. PMC: 7170889. DOI: 10.1038/s41467-020-15742-7. View

Manaster Y, Shipony Z, Hutzler A, Kolesnikov M, Avivi C, Shalmon B . Reduced CTL motility and activity in avascular tumor areas. Cancer Immunol Immunother. 2019; 68(8):1287-1301. PMC: 11028152. DOI: 10.1007/s00262-019-02361-5. View

Nguyen K, Vrabel M, Mantooth S, Hopkins J, Wagner E, Gabaldon T . Localized Interleukin-12 for Cancer Immunotherapy. Front Immunol. 2020; 11:575597. PMC: 7593768. DOI: 10.3389/fimmu.2020.575597. View

10.

Chakraborty K, Bose A, Pal S, Sarkar K, Goswami S, Ghosh D . Neem leaf glycoprotein restores the impaired chemotactic activity of peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients by maintaining CXCR3/CXCL10 balance. Int Immunopharmacol. 2008; 8(2):330-40. DOI: 10.1016/j.intimp.2007.10.015. View

11.

Qi G, Gao Y, Wang L, Wang H . Self-Assembled Peptide-Based Nanomaterials for Biomedical Imaging and Therapy. Adv Mater. 2018; 30(22):e1703444. DOI: 10.1002/adma.201703444. View

12.

Feng S, Li J, Luo Y, Yin T, Cai H, Wang Y . pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS One. 2014; 9(6):e100732. PMC: 4071001. DOI: 10.1371/journal.pone.0100732. View

13.

Zanchett Schneider N, Cerella C, Oliveira Simoes C, Diederich M . Anticancer and Immunogenic Properties of Cardiac Glycosides. Molecules. 2017; 22(11). PMC: 6150164. DOI: 10.3390/molecules22111932. View

14.

Xu H, Van der Jeught K, Zhou Z, Zhang L, Yu T, Sun Y . Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. J Clin Invest. 2021; 131(10). PMC: 8121519. DOI: 10.1172/JCI146832. View

15.

Power Coombs M, Harrison M, Hoskin D . Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells. Cancer Lett. 2016; 380(2):424-433. DOI: 10.1016/j.canlet.2016.06.023. View

16.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

17.

Kundu M, Majumder R, Das C, Mandal M . Natural products based nanoformulations for cancer treatment: current evolution in Indian research. Biomed Mater. 2021; 16(4). DOI: 10.1088/1748-605X/abe8f2. View

18.

Mu X, Zhang M, Wei A, Yin F, Wang Y, Hu K . Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases. Nanoscale. 2021; 13(19):8998-9008. DOI: 10.1039/d0nr08024a. View

19.

Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X . Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Lett. 2021; 21(10):4231-4240. DOI: 10.1021/acs.nanolett.1c00209. View

20.

Jiang Z, Wang W, Xu C, Xie Y, Wang X, Zhang Y . Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer. Cancer Lett. 2021; 515:36-48. DOI: 10.1016/j.canlet.2021.05.019. View